Pharma Capital

'2016 was a complete turnaround year for Akers Biosciences', says CEO John Gormally

Akers Biosciences Inc (LON:AKER, NASDAQ:AKER) chief executive John Gormally runs Proactive through the firm's full year results -describing second-half sales of their heparin allergy product as strong.

Akers also expects its rapid cholesterol test, which is being sold direct to consumers under the First Check brand, to make a significant contribution while its app-connected wellness products will add to the commercial momentum.

 

View full AKR profile

Akers Biosciences, Inc. Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.